3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Burkitt Lymphoma
15
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Leukemia, Biphenotypic, Acute
4
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, Mantle-Cell
3
Leukemia, Myeloid, Accelerated Phase
3
Down Syndrome
3
Blast Crisis
3
Osteosarcoma
2
Myeloproliferative Disorders
2
Leukemia, Myeloid, Acute
2
Leukemia
2
Blastic Plasmacytoid Dendritic Cell Neoplasm
2
Anemia, Refractory, with Excess of Blasts
2
Waldenstrom Macroglobulinemia
1
Urothelial Carcinoma of the Bladder
1
Thrombocythemia, Essential
1
Sezary Syndrome
1
Sarcoma, Ewing
1
Rhabdoid Tumor
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Recurrence
1
Primary Myelofibrosis
1
Precancerous Conditions
1
Polycythemia Vera
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Oropharyngeal Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Interventions
Tretinoin
2
Arsenic Trioxide
2
arsenous acid
1
Mitoxantrone
1
Methotrexate
1
Mercaptopurine
1
Lisaftoclax
1
Idarubicin
1
Gemtuzumab
1
Cytarabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Promyelocytic, Acute
×
Methotrexate
×
30 days
×
Clear all
NCT02688140
2026-05-29
TUD-APOLLO-064
Technische Universität Dresden
Phase 3
Completed
133 enrolled